Riskpilot← Back to searchSign inGet full accessNewbury Pharmaceuticals AB
ABActiveOrg 5592742463LundWholesale of pharmaceutical and medical goods · NACE 4646Est. 20205 employees
Revenue 2025
SEK 26,7M
+56% vs 2024
EBITDA margin
-59.2%
-20% vs 2024
Equity ratio
57.0%
Financial strength
Net profit 2025
SEK -23,6M
-56% vs 2024
| Revenue | SEK 26,7M | +56% |
| EBITDA | SEK -15,8M | -20% |
| Net profit | SEK -23,6M | -56% |
| Total assets | SEK 79,5M | -13% |
| Equity | SEK 45,3M | -16% |
| Employees | 5 | — |
Legal name
Newbury Pharmaceuticals AB
Org number
5592742463
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
30 september 2020
Share capital
SEK 970 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av en av ledamöterna i förening med Hellqvist, Per Fredrik Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolaget skall bedriva handel med läkemedel, naturläkemedel, naturmedel, hälso- och sjukvårdsprodukter samt äga och förvalta aktier och andelar i dotterbolag och därmed förenlig verksamhet.
Address
Lund
Email
info@newburypharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1 312 | 2 733 | 17 122 | 26 721 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −5 131 | −13 079 | −20 185 | −13 206 | −15 807 |
| Depreciation & amort. | −0 | −94 | −343 | −824 | −4 746 |
| EBIT | −5 131 | −13 173 | −20 528 | −14 030 | −20 553 |
| Net financials | −49 | 64 | 278 | −1 109 | −4 685 |
| Profit before tax | −5 159 | −13 109 | −20 250 | −15 139 | −23 587 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −5 159 | −13 109 | −20 250 | −15 139 | −23 587 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 42 040 | 88 742 | 69 907 | 91 918 | 79 544 |
| Equity | 38 887 | 70 872 | 50 691 | 53 628 | 45 302 |
| Long-term debt | 0 | 12 076 | 11 769 | 9 508 | 3 745 |
| Short-term debt | 3 153 | 5 794 | 7 447 | 28 782 | 30 497 |
| Total debt | 3 153 | 17 870 | 19 216 | 38 290 | 34 242 |
EBITDA margin
-59.2%
This company
15.8%
Market median
-475% vs market
20212025
Equity ratio
57.0%
This company
38.2%
Market median
+49% vs market
20212025
Return on equity
-52.1%
This company
18.4%
Market median
-383% vs market
20212025
Net profit margin
-88.3%
This company
8.1%
Market median
-1190% vs market
20212025
Asset turnover
0.34×
This company
1.12×
Market median
-70% vs market
20212025
Debt / equity
0.76×
This company
0.62×
Market median
+23% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
KA Chief Executive Officer | Chief Executive Officer | 2020 |
PM Chief Auditor | Chief Auditor | 2020 |
CA Chief Auditor | Chief Auditor | 2026 |
PF External Signatory | External Signatory | 2025 |
| Former (1) | ||
LE Chief Executive Officer | Chief Executive Officer | 2021 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2025 | |
| Board of Directors | 2026 | |
| Board of Directors | 2024 | |
| Board of Directors | 2020 | |
| Former (2) | ||
| Board of Directors | 2020 – 2026 | |
| Board of Directors | 2022 – 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Newbury Pharmaceuticals AB (this company)
Newbury Pharmaceuticals S.A.NEWBURY PHARMACEUTICALS S.A.Board members of Newbury Pharmaceuticals AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Alexius Tiger Karlsson | Chief Executive Officer | 0 companies |
| Per Martin Henriksson | Chief Auditor | 0 companies |
| Lars Enghave Minor | Chief Executive Officer | 0 companies |
| Curt Arne Jesper Ahlkvist | Chief Auditor | 0 companies |
| Per Fredrik Hellqvist | External Signatory | 0 companies |
| Ivaylo Stefano Georgiev | Chairman | 0 companies |
| Johan Henrik Orvelin | Board of Directors | 0 companies |
| Anil Okay | Board of Directors | 0 companies |
| Ramon Vila Ramos | Board of Directors | 0 companies |
| Andreas Hedskog | Board of Directors | 0 companies |
| Johan Henrik Strömqvist | Board of Directors | 0 companies |